The Jean Boulle Group invests in promising assets and projects where long-term value can be created. The Group works with management teams and others to optimize the structure, strategy and development of its investments and accesses private as well as public capital.
The Jean Boulle Group's interests span a wide range of areas, but the Group is principally active in natural resources, medical technology and philanthropy.
Jean-Raymond Boulle (born 1950) started his career at the De Beers Diamond Trading Company (“DTC”) where he worked for ten years, in Zaire, Sierra Leone and Antwerp, Belgium. Thereafter he established Boulle Inc. in Dallas, Texas, US.
In 1984 he began exploring for diamonds, first in Minnesota, then in Arkansas.
In 1987 he formed Arkansas Diamond Development Co., to carry out exploration work on the Crater of Diamonds State Park in Arkansas.
Jean Raymond Boulle is the founder of Diamond Fields Resources Inc (which Inco purchased for CND$ 4.3 billion), Diamond Fields International Ltd, America Mineral Fields Inc, and Titanium Resources Group Ltd; four publicly traded companies with deposits of nickel, cobalt, copper, zinc, titanium and diamonds.
Jean Raymond Boulle is also a member of the Board of the Corporate Council on Africa (‘CCA’). Mr Boulle has maintained a longstanding involvement with the CCA since it was established in 1993 to promote business and investment between the United States and the nations of Africa.
Boulle was chairman, founder and CEO as well as a major shareholder of Diamond Fields (Diamond Fields Resources Inc. TSE:DFR) which commenced trading on the Vancouver Stock Exchange on April 6, 1993 and, in late 1994, discovered nickel, copper and cobalt ore bodies at Voisey’s Bay Mine in Labrador, Canada. The Voisey’s Bay Mine deposit was estimated to contain 141 million tonnes at 1.6% nickel.
Boulle and Robert Friedland worked together in Diamond Fields and, in 1996, the Voisey’s Bay Mine Project was purchased by Inco for CND$ 4.3 billion.
Jean Boulle Group
The Jean Boulle Group has been a member of the US Corporate Council on Africa since the Council's inception in 1993.Jean Raymond Boulle was himself appointed to the Board of the Corporate Council on Africa in early 2021. The Council was established to promote business and investment between the United States and the nations of Africa, and is the leading U.S. business association focused solely on connecting business interests in the continent.
The Boulle Mining Group is headquartered in Luxembourg and founded American Mineral Fields in 1995 (later renamed Adastra Minerals) listed on the London Stock Exchange’s Alternative Investment Market and the Toronto Stock Exchange.
Adastra Minerals developed mining projects in the Democratic Republic of Congo and a joint venture with the government of the Democratic Republic of Congo to re-treat the Kolwezi tailings project. Adastra Minerals was purchased in August 2006 by First Quantum Minerals, a mining company then with dual listings on the Toronto Stock Exchange and the London Stock Exchange.
In 2001, Boulle Mining Group Luxembourg acquired the Sierra Rutile Project (a producer of natural rutile) and of the Sierra Minerals SML Bauxite Mine in Sierra Leone, West Africa which became part of Titanium Resources Group, taken public on the London Stock Exchange’s Alternative Investment Market in August 2005.
His mining group’s subsidiary company, Greenland Gold Resources Ltd is in Greenland exploring for nickel, copper, cobalt, platinum group elements, titanium and graphite.
Boulle Mining Group Luxembourg was the largest shareholder in World Titanium Resources, the Australian Securities Exchange-listed discoverers and owners of the Toliara Sands titanium deposit in Madagascar. World Titanium Resources was delisted from ASX on 30 January 2017 and is now privately owned as World Titane Holdings Limited.
Together with the Government of Mauritius, Boulle is one of the three controlling shareholders of Omnicane, a publicly listed company on the Stock Exchange of Mauritius. Omnicane owns sugarcane plantations in Mauritius and produces refined sugar. Omnicane also generates around 30% of the island’s electricity for the Grid and 40% of the country’s renewable bagasse-based energy.
Boulle’s companies have conducted mining and exploration operations for gold, copper, nickel, zinc, and diamonds and other precious and semi-precious stones in South Africa, Namibia, Liberia, Madagascar, Democratic Republic of Congo, Zambia, Finland, Canada, and Brazil.
Since 1996, Boulle has made numerous ongoing donations and contributions to charity, hospitals, museums, animal conservation, and the World Wide Fund For Nature.
In 2007, Boulle was made a Commander of the Order of the Rokel, one of the highest orders of merit of Sierra Leone. This was given by the country of Sierra Leone, in recognition, for having restarted the economy of Sierra Leone with a titanium and a bauxite mine.
On 2 December 2014, the Boulle Group’s Tendyne Holdings Inc. start-up company announced the world’s first successful Human Heart Mitral Valve implants at the Royal Brompton Hospital in London, England.
In September 2015, Jean Boulle Medtech Ltd, a founding investor of Tendyne, announced that Abbott Laboratories (NYSE: ABT) had closed its acquisition of Tendyne. Abbott Laboratories thereby acquired the remaining shares of Tendyne it did not already own for US$250 million plus US$150 million in potential future payments tied to regulatory milestones. This acquisition culminated a relationship that began when Jean Boulle Medtech welcomed Abbott Laboratories as an early strategic investor in Tendyne. Jean Boulle Medtech worked with Tendyne’s most recent investor, Apple Tree Partners, in helping to complete the transaction.
On 3 February 2020, the Tendyne transcatheter mitral heart valve implant which the Group developed through Tendyne Holdings Inc. received CE Mark approval from the European Union.
On 11 May 2017, the group signed an agreement with AkzoNobel for the production of its aviation-grade Sun King® Diamond Coating for the private and commercial jet markets.
On 27 April 2020, TTxD, an immunotherapy biotech company founded by Jean Boulle Medtech, announced the testing of a unique strategy for treating Acute Respiratory Distress Syndrome, which could prove to be highly effective in saving the lives of COVID–19 patients.
On 1 September 2020, TTxD noted the results of a landmark clinical trial published in peer-reviewed journal Cell showing that trained immunity through the use of BCG vaccination can reduce respiratory tract infections by 80% amongst elderly people including, potentially, COVID-19. This trial provided further evidence that BCG induces trained immunity responses and validates the approach followed by TTxD which uses advanced bioengineering methods to produce nanobiologic therapeutics based upon components of the BCG vaccine. The Trial was coordinated by Mihai G. Netea, founder and Chair of TTxD’s scientific advisory board and Professor of Experimental Internal Medicine at Radboud UMC.
Copyright © 2019 Jean Boulle Group. All rights reserved.